Veterinary Vaccines Market by Disease (Swine Pneumonia, Avian Influenza, Rabies, Coccidiosis, Brucellosis, Canine Distemper), Product Type (Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, Recombinant Vaccines, and DNA Vaccines) and Animal Type (Companion animals, Cattle, Fish, Pigs, Poultry, and Sheep): Global Opportunity Analysis and Industry Forecast, 2021-2027
| ID: VPR/HC/117 | Publishing Year: July 2020 | Pages: 181 | Format: |
Global Veterinary Vaccines Market was valued at $7.46 billion in 2019, and is expected to reach $12.92 billion by 2027, registering a CAGR of 7.11 % from 2021 to 2027.
Veterinary Vaccines are injected into body of animals to prevent transmission of diseases and provide protection for animal and human beings, as human beings are highly dependent on animals for food, milk, meat and other products such as wool. Veterinary Vaccines are to enhance the wellbeing and welfare of animals and their companion, it also increase livestock farming in a cost-effective manner and prevent animal-to-human transmission. Rabies vaccines, rinderpest vaccines are most widely used Veterinary Vaccines, preventing the transmission of infectious agents by imitating the immunity, whichis acquired naturally.
Increase in population of animals in developing countries, which have led to increase in incidence of diseases among animals is primary growth driver for Veterinary Vaccines Market. In addition, increase investmentin R&D in vaccines that inhibit the growth of antibiotic-resistant organisms boosts the growth of the market. Nevertheless, lack of knowledge of animal health and the risk of adverse effect on human and other animal health vaccines on Veterinary Vaccines hinders the growth of the market. Live attenuated vaccines are rapidly adopting recombinant vaccine solutions, which will provide this market with further growth opportunities in the near future.
Segment Insight
The Veterinary Vaccines Market is segmented based on Disease, Product Type, Animal Type and Region. Based on Disease, it is classified intoswine pneumonia, avian influenza, rabies, coccidiosis, brucellosis, canine distemper. Based on Product Type, it is divided intoattenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, recombinant vaccines, and DNA vaccines. Based on Animal Type it is classified into companion animals, cattle, fish, pigs, poultry, and sheep.
By Disease Insight
The Veterinary Vaccines Market is segmented by disease intoswine pneumonia, avian influenza, rabies, coccidiosis, brucellosis, canine distemper.
By Product Type Insight
The Veterinary Vaccines Market is segmented by product type into attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, recombinant vaccines, and DNA vaccines. Attenuated vaccines reduce the need for booster vaccines as it can provide stronger immunity as compared to other vaccines, which contributes positively to the growth of the market for veterinary vaccines.
By Animal Type Insight
The Veterinary Vaccines Market is segmented by animal type into companion animals, cattle, fish, pigs, poultry, and sheep. Companion animals are greatly in contact with human beings which necessitates use of Veterinary Vaccines to prevent transmission of diseases. Increasing the number of adoptions of these companion animals and increasing awareness about the importance of vaccines for dogs and cats as well help to boost the growth of the market.
Major Key Players of Global Veterinary Vaccines Market:
The Report Provides a Comprehensive Analysis of the Key Players Operating in the Global Veterinary Vaccines Market, such as Zoetis, BoehringerIngelheim, Elanco, Merck Animal Health, Ceva, Phibro Animal Health, Virbac ,Vetoquinol, Hester Biosciences , HIPRA. Most of the key players in Veterinary vaccines are focusing on business expansion to gain a higher revenue share through the adoption of strategies, such as mergers and acquisitions and new product development.
Veterinary Vaccines Market key Segments:
By Disease
- Swine pneumonia
- Avian influenza
- Rabies
- Coccidiosis
- Brucellosis
- Canine distemper
By Product Type
- Attenuated vaccines
- Inactivated vaccines
- Subunit vaccines,
- Toxoid vaccines
- Conjugate vaccines
- Recombinant vaccines
- DNA vaccines
By Animal Type
- Companion animals,
- Cattle
- Fish
- Pigs,
- Poultry
- Sheep
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Argentina
- Turkey
- South Africa
- Rest of LAMEA
Frequently Asked Questions
TABLE OF CONTENTS:
CHAPTER 1 MARKET INTRODUCTION
1.1. REPORT OVERVIEW
1.2. SCOPE OF THE STUDY
1.3. PRIMARY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
CHAPTER 2 EXECUTIVE SUMMARY
2.1. C-LEVEL EXECUTIVE’SOVERVIEW AND PERSPECTIVES
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. PRINCIPAL FINDINGS
3.2.1. Key investment pockets
3.2.2. Leading winning strategies
3.2.3 Key Player Positioning
3.3. PORTERS FIVE FORCES OF COMPETITIVE ANALYSIS
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Impact Analysis
3.5. IMPACT OF COVID-19 ON THIS MARKET
CHAPTER 4 VETERINARY VACCINES MARKET, BY DISEASE
4.1. SYNOPSIS
4.1.1. Market size and forecast
4.2. SWINE PNEUMONIA
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. AVIAN INFLUENZA
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. RABIES
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. COCCIDIOSIS
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.6. BRUCELLOSIS
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast
4.7. CANINE DISTEMPER
4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast
CHAPTER 5 VETERINARY VACCINES MARKET, BY PRODUCT TYPE
5.1. SYNOPSIS
5.1.1. Market size and forecast
5.2. ATTENUATED VACCINES
5.2.1. Key market trends
5.2.2. Growth factors and opportunities
5.2.3. Market size and forecast
5.3. INACTIVATED VACCINES
5.3.1. Key market trends
5.3.2. Growth factors and opportunities
5.3.3. Market size and forecast
5.4. SUBUNIT VACCINES
5.4.1. Key market trends
5.4.2. Growth factors and opportunities
5.4.3. Market size and forecast
5.5. TOXOID VACCINES
5.5.1. Key market trends
5.5.2. Growth factors and opportunities
5.5.3. Market size and forecast
5.6. CONJUGATE VACCINES
5.6.1. Key market trends
5.6.2. Growth factors and opportunities
5.6.3. Market size and forecast
5.7. RECOMBINANT VACCINES
5.7.1. Key market trends
5.7.2. Growth factors and opportunities
5.7.3. Market size and forecast
5.8. DNA VACCINES
7.8.1. Key market trends
7.8.2. Growth factors and opportunities
7.8.3. Market size and forecast
CHAPTER 6VETERINARY VACCINES MARKET, BY ANIMAL TYPE
6.1. SYNOPSIS
6.1.1. Market size and forecast
6.2. COMPANION ANIMALS
6.2.1. Key market trends
6.2.2. Growth factors and opportunities
6.2.3. Market size and forecast
6.3. CATTLE
6.3.1. Key market trends
6.3.2. Growth factors and opportunities
6.3.3. Market size and forecast
6.4. FISH
6.4.1. Key market trends
6.4.2. Growth factors and opportunities
6.4.3. Market size and forecast
6.5. PIGS
6.5.1. Key market trends
6.5.2. Growth factors and opportunities
6.5.3. Market size and forecast
6.6. POULTRY
6.6.1. Key market trends
6.6.2. Growth factors and opportunities
6.6.3. Market size and forecast
6.7. SHEEP
6.7.1. Key market trends
6.7.2. Growth factors and opportunities
6.7.3. Market size and forecast
CHAPTER 7VETERINARY VACCINES MARKET, BY REGION
7.1 SYNOPSIS
7.2 North America
7.2.1 Key market trends
7.2.2 Competitive scenario
7.2.3 Key growth factors and opportunities
7.2.4 Market size and forecast
7.3 Europe
7.3.1 Key market trends
7.3.2 Competitive scenario
7.3.3 Key growth factors and opportunities
7.3.4 Market size and forecast
7.4 Asia Pacific
7.4.1 Key market trends
7.4.2 Competitive scenario
7.4.3 Key growth factors and opportunities
7.4.4 Market size and forecast
7.5 LAMEA
7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. ZOETIS
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Product portfolio
8.1.4. Business performance
8.1.5. Key strategic moves and developments
8.2. BOEHRINGER INGELHEIM
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. ELANCO
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. MERCK ANIMAL HEALTH
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. CEVA
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. PHIBRO ANIMAL HEALTH
8.6.1. Company overview
8.6.2. Company Snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. VIRBAC
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. VETOQUINOL
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. HESTER BIOSCIENCES
8.8.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. HIPRA
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product portfolio
8.10.4. Key strategic moves and developments
Type Here for figure.